Loading...

APC/Cyanine7 anti-human CD45RA Antibody

Pricing & Availability
Clone
HI100 (See other available formats)
Regulatory Status
RUO
Workshop
IV N906
Other Names
GP180, L-CA, LCA, LY5, T200, PTPRC
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
HI100_APCCy7_011011
Human peripheral blood lymphocytes were stained CD45RA (clone HI100) APC/Cyanine7 (filled histogram) or mouse IgG2b, κ APC/Cyanine7 isotype control (open histogram).
  • HI100_APCCy7_011011
    Human peripheral blood lymphocytes were stained CD45RA (clone HI100) APC/Cyanine7 (filled histogram) or mouse IgG2b, κ APC/Cyanine7 isotype control (open histogram).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
304127 25 tests 111€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304128 100 tests 269€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45RA is a 205-220 kD single chain type I glycoprotein. It is an exon 4 splice variant of the tyrosine phosphatase CD45. The CD45RA isoform is expressed on resting/naïve T cells, medullary thymocytes, B cells and monocytes. CD45RA enhances both T cell receptor and B cell receptor signaling. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1. CD45 isoform expression can change in response to cytokines.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for relevant formats of this clone) include: inhibition of CD45 functions2, immunohistochemical staining of frozen tissue sections3 and formalin-fixed paraffin-embedded tissue sections4, and immunocytochemistry15,16.

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Yamada T, et al. 2002. J. Biol. Chem. 277:28830. (WB, Block)
  3. Weninger W, et al. 2003 J. Immunol. 170:4638. (IHC-F)
  4. Imanguli MM, et al. 2009. Blood. 113:3620 (IHC-P)
  5. Roque S, et al. 2007. J. Immunol. 178:8028. (FC) PubMed
  6. Smeltz RB. 2007. J. Immunol. 178:4786. (FC) PubMed
  7. Palendira U, et al. 2008. Blood (FC) PubMed
  8. Kuttruff S, et al. 2009. Blood 113:358. (FC) PubMed
  9. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  10. Alanio C, et al. 2010. Blood 115:3718. (FC) PubMed
  11. Iannello A, et al. 2010. J. Immunol. 184:114. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Guereau-de-Arellan M, et al. 2011. Brain. 134:3578. PubMed
  14. Canque B, et al. 2000. Blood 96:3748. (ICC)
  15. Imanguli MM, et al. 2009. Blood 13:3620. (ICC)
  16. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Li Y, et al. 2022. J Med Virol. 94:3998. PubMed
  2. Chen Y, et al. 2022. Sci Immunol. 7:eabp8328. PubMed
  3. Omer-Javed A, et al. 2022. Cell. 185:2248. PubMed
  4. Jung S, et al. 2022. Cell Rep. 40:111138. PubMed
  5. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  6. Terahara K, et al. 2022. iScience. 25:104959. PubMed
  7. Ke F, et al. 2023. Elife. 12:. PubMed
  8. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  9. Scala S, et al. 2023. Nat Commun. 14:3068. PubMed
  10. Chagraoui J, et al. 2021. Cell Stem Cell. 28(1):48-62.e6. PubMed
  11. Shoda H, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1308-y. PubMed
  12. Berres M, et al. 2014. J Exp Med. 211:669. PubMed
  13. Ishizaka A, et al. 2016. J Virol. 90: 5665 - 5676. PubMed
  14. Nagafuchi Y, et al. 2016. Sci Rep. 6:29338. PubMed
  15. Ho T, et al. 2016. Blood. 128: 1671 - 1678. PubMed
  16. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  17. Todd J, et al. 2016. PLoS Med. 13:e1002139. PubMed
  18. Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed
  19. Qi Q, et al. 2016. PLoS Pathog. 12:e1005892. PubMed
  20. Björklund &, et al. 2016. Nat Immunol. 17:451-460. PubMed
  21. Ma X et al. 2019. eLife. 8 pii: e42426. PubMed
  22. Xiao X, et al. 2019. Cell Discov. 5:2. PubMed
  23. Hu W, et al. 2021. Vaccines (Basel). 9:. PubMed
  24. Masson J, et al. 2017. PLoS One.. 10.1371/journal.pone.0183931. PubMed
  25. Zheng S, et al. 2018. Mol Syst Biol. 14:e8041. PubMed
  26. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  27. Wang X, et al. 2021. Cell Discovery. 7(1):60. PubMed
  28. Bulgarelli J, et al. 2021. Front Immunol. 12:778459. PubMed
  29. Jung JH, et al. 2021. Nat Commun. 12:4043. PubMed
  30. Nakasone H, et al. 2021. Commun Biol. 4:1177. PubMed
  31. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  32. Nakachi S, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1309-x. PubMed
  33. Chen Y, et al. 2020. Cell. 1496:183. PubMed
  34. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  35. Keller B, et al. 2016. J Exp Med. 213: 1185 - 1199. PubMed
  36. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  37. Crippa S, et al. 2019. J Clin Invest. 129:1566. PubMed
  38. Yamaguchi K, et al. 2018. Cancer Sci. 109:3032. PubMed
  39. Tomellini E, et al. 2020. Cell Reports. 28(4):1063-1073.e5.. PubMed
  40. Mann EH, et al. 2019. J Immunol. 202:684. PubMed
RRID
AB_10708419 (BioLegend Cat. No. 304127)
AB_10708419 (BioLegend Cat. No. 304128)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane (exon 4 splicing of CD45 gene), 205-220 kD
Distribution

B cells, naïve T cells, monocytes

Function
Enhances TCR and BCR signaling
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, Monocytes, T cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.

Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45RA on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45RA Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD45RA HI100 FC
Biotin anti-human CD45RA HI100 FC
FITC anti-human CD45RA HI100 FC
PE anti-human CD45RA HI100 FC,SB
PE/Cyanine5 anti-human CD45RA HI100 FC
Purified anti-human CD45RA HI100 FC,CyTOF®,ICC,IHC-P,IHC-F,SB
Alexa Fluor® 488 anti-human CD45RA HI100 FC
Alexa Fluor® 647 anti-human CD45RA HI100 FC,IHC-P
Pacific Blue™ anti-human CD45RA HI100 FC
Alexa Fluor® 700 anti-human CD45RA HI100 FC
PerCP/Cyanine5.5 anti-human CD45RA HI100 FC,SB
PE/Cyanine7 anti-human CD45RA HI100 FC
APC/Cyanine7 anti-human CD45RA HI100 FC
Brilliant Violet 421™ anti-human CD45RA HI100 FC,IHC-P
Brilliant Violet 570™ anti-human CD45RA HI100 FC
Brilliant Violet 605™ anti-human CD45RA HI100 FC
Brilliant Violet 650™ anti-human CD45RA HI100 FC
Brilliant Violet 711™ anti-human CD45RA HI100 FC
Brilliant Violet 785™ anti-human CD45RA HI100 FC
Brilliant Violet 510™ anti-human CD45RA HI100 FC
Purified anti-human CD45RA (Maxpar® Ready) HI100 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD45RA HI100 FC
APC/Fire™ 750 anti-human CD45RA HI100 FC
PerCP anti-human CD45RA HI100 FC
FITC anti-human CD45RA HI100 FC
TotalSeq™-A0063 anti-human CD45RA HI100 PG
Alexa Fluor® 594 anti-human CD45RA HI100 IHC-P
TotalSeq™-B0063 anti-human CD45RA HI100 PG
TotalSeq™-C0063 anti-human CD45RA HI100 PG
Brilliant Violet 750™ anti-human CD45RA HI100 FC
Spark NIR™ 685 anti-human CD45RA HI100 FC
APC anti-human CD45RA HI100 FC
PE/Fire™ 640 anti-human CD45RA HI100 FC
PE/Fire™ 700 anti-human CD45RA Antibody HI100 FC
Spark YG™ 581 anti-human CD45RA HI100 FC
TotalSeq™-D0063 anti-human CD45RA HI100 PG
Spark Violet™ 423 anti-human CD45RA HI100 FC,IHC-P
GMP FITC anti-human CD45RA HI100 FC
PE/Cyanine7 anti-human CD45RA HI100 FC
PE/Dazzle™ 594 anti-human CD45RA HI100 FC
APC/Fire™ 750 anti-human CD45RA HI100 FC
Spark UV™ 387 anti-human CD45RA HI100 FC
GMP APC anti-human CD45RA HI100 FC
TotalSeq™-Bn0063 anti-human CD45RA HI100 SB
Spark Blue™ 550 anti-human CD45RA HI100 FC
GMP PE/Dazzle™ 594 anti-human CD45RA HI100 FC
GMP APC/Fire™ 750 anti-human CD45RA HI100 FC
Spark PLUS UV395™ anti-human CD45RA HI100 FC
Spark Red™ 718 anti-human CD45RA HI100 FC
APC/Fire™ 810 anti-human CD45RA HI100 FC
PE/Fire™ 810 anti-human CD45RA HI100 FC
Spark Blue™ 574 anti-human CD45RA (Flexi-Fluor™) HI100 FC
Go To Top Version: 5    Revision Date: 06-05-2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account